Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
Clopidogrel is the drug of choice for treatment of NSTEMI Heart Attacks, Peripheral Vascular Disease as Well as Ischaemic Strokes and TIS's because it is cheaper than its rivals excluding Aspirin for Cardiovascular Disease, which for POST-MI patients is always combined with Clopidogrel, Prasugrel or Ticagrelor, simply because clinicians know that, as with any medication, a certain number of people will get no beneficial reaction to taking it, either because their bowel doesn't absorb it or their liver can't metabolise it.
As Stroke patients are the smallest of these groups and are also given as Clopidogrel as the Anti-agregant of choice, it made sense for GDR to focus on this group first.
The MI patient group would probably be next to focus on, bearing in mind the significant secondary event rate following Coronary Artery Stenting and MI. This would have a huge addressable market.
Genome Testing in a lab is probably preferable, because studying the cells under a microscope also allows lab staff to occasionally identify abnormalities which are outside of the test specifically requested, but unless the hospital treating the patient happens to be one of the 12 or so Genome hubs, this will always take a few days and up to a week as it has to be posted or couriered each way and there are many different Genome tests for many different conditions fighting for space in the incubators. This increases constantly due to medical breakthroughs based on the World Genome mapping project and database.
If the FDA fully approve the GDR POC test, it will almost certainly be used more than a lab test simply due to the Capacity and Rapid Result perspective.
All in my opinion.
I'm not trying to ramp this but as a clinician would be delighted if it comes off.
I like many am 80% down on this but hope to make this back up over the next year or 2
Yana, not everyone has spare cash to invest, some have mortgages and other requirements such as for their family.
Also if the CEO had done a share issue and then gobbled up a chunk of it, you'd probably cry fowl over that too!!
I read the 22-23 accounts statement again this morning and all progressing well. Since then, things have progressed even faster with acquisitions.
Any news on potential Sandbox and projected earnings/profits would be great plus trade shows etc.
As I've said a couple of times over the past 8 weeks 20th December the likely results announcement and future projections day.
Simply based on the date of the announcement last year.
I don't buy the idea of "They announced it on a Tuesday last year idea."
The board seem less fickle than that and as long as the 20th doesn't fall on a weekend, I suspect that the date is electronically selected as the correct date for the announcement every year now.
I expect that the stated FYr results will not influence the SP however like most on here, I expect the forward projection to lift or rocket the SP, depending on how they word it.
Hi Mr Russell
Glad that you chose GST as it has a vast market sector and should be fun to watch over the next month and onwards into the next 7-10 years by which time it could be huge🎉😁😀🤞
Good luck with your memory.
Crosswords, wordsearch, sudoku, and daytime quizzes should slow down the confusion
B. w
Porsh
We know that GST is building stronger and wiser, so for heaven's sake be kind to each other.
I have no doubt that GST is now making some prifits so a re-valuation is likely to occur in the next 2 months, with feedback immediately prior to Christmas.
Most of the comments on this board includes or are purely for the purposes of belittling others, which has a negative psychological effect on the person posting the message